We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.20 | -0.16% | 127.31 | 127.73 | 126.76 | 127.32 | 2,638,194 | 17:50:49 |
From May 2021 to May 2024
By Colin Kellaher
Shares of Merck & Co. rose more than 8% in premarket trading Friday after the drugmaker said the experimental pill it is developing with Ridgeback Biotherapeutics reduced the risk of hospitalization or death by about 50% compared to a placebo in patients with mild or moderate Covid-19.
The Kenilworth, N.J., company said it plans to file for emergency-use authorization from the U.S. Food and Drug Administration as soon as possible.
Approval would make the drug, called molnupiravir, the pandemic's first easy-to-use, at-home treatment.
Merck shares, which closed Thursday at $75.11, were recently up 8.2% to $81.30 in premarket trading, near their 52-week high of $81.52 reached in January.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 01, 2021 09:13 ET (13:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
